key: cord-0924246-wgpoyp4o
authors: Lee, Yi; Jehangir, Qasim; Kaur, Jasmeet; Abdou, Asrar; Ibrahim, Mohammed; Mandeel, Mohamed N.; Dixit, Priyadarshini; Lal, Amar; Kulkarni, Mayuri; Mohammed, Yaqub N.; Pulipati, Priyanjali; Duong, Jacky
title: Increased Mortality in Antecedent Combined Renin–Angiotensin System Inhibitors and Antiplatelets Compared With Antiplatelets Alone in Hospitalized Patients With COVID-19
date: 2021-06-25
journal: Am J Ther
DOI: 10.1097/mjt.0000000000001410
sha: a94e9df15581edcbd304b587441be17cad011e5c
doc_id: 924246
cord_uid: wgpoyp4o

Supplemental Digital Content is Available in the Text.

To the Editor: Novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has resulted in a high-mortality pandemic. Angiotensin-converting enzyme 2 (ACE2) promotes systemic vasodilation and has antiinflammatory effects. 1 ACE2 also serves as a receptor for SARS-CoV2 viral entry into the host cells. 2 Some studies suggest that inhibitors of the renin-angiotensin system (RAS) including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers increase ACE2 expression in the lung, heart, and kidney tissues 3, 4 ; however, another study suggests the opposite. 5 With initial speculation that RAS inhibitors may worsen clinical outcomes in patients with COVID-19, a study from Italy showed that patients taking prehospital RAS inhibitors had a reduced risk of inpatient death. 6 SARS-CoV-2 infection is associated with platelet hyperreactivity that is independent of ACE2 receptors because these receptors are not detected on platelets. 7 Platelet activation likely contributes to the thromboinflammation in COVID-19, and the inhibition of pathways related to their activation can possibly improve the outcomes during COVID-19 infection. 8 However, the benefit of prehospitalization usage of low-dose aspirin remained uncertain. [9] [10] [11] The outcomes of combined RAS inhibitors and antiplatelets are not well studied, and to the best of our knowledge, there is no study on the outcomes of hospitalized patients with COVID-19 who were taking both RAS inhibitors and antiplatelets compared with antiplatelets alone. Therefore, in this study, we aimed to assess the outcomes of patients taking both RAS inhibitors and antiplatelets before hospitalization. This is a retrospective, multi-institutional (8 trinity health system hospitals) cohort study of patients older than 18 years admitted to Saint Joseph Mercy Health System hospitals between March 10, 2020, and May 3, 2020, with polymerase chain reaction proven SARS-CoV-2 infection. The study protocol was approved by the Saint Joseph Mercy Oakland Institutional Review Board; individual patient consent was waived. A broad spectrum of variables was collected, including baseline demographic characteristics (age, sex, race, and social history), comorbid conditions (coronary artery disease, heart failure, atrial fibrillation [AFib], hypertension, diabetes mellitus [DM], pulmonary disease, chronic kidney disease [CKD], autoimmune disease, and cancer), and maximum oxygen requirement. Group 1 was defined as prehospital antiplatelet usage alone, and group 2 was defined as prehospital RAS inhibitors and antiplatelet usage. The primary outcome was mortality within 90 days. The secondary outcomes were readmission rate, intensive care unit (ICU) admission rate, and intubation rate. Categorical variables were reported as frequencies, and continuous variables as mean 6SD or median. For comparisons of continuous variables, the Student t-test was used; for categorical variables, the x 2 test was used. Multivariable logistic regression was performed to identify independent predictors of 90-day mortality. Survival curves were generated using the Kaplan-Meier method and compared by using the log-rank statistic. All analyses were performed using R version 1.2.1335. All tests were two-sided with P ,0.05 indicating statistical significance.

A total of 144 patients were included in the analysis, 53.8% were male. 66.1% were African American, 26.6% White, and 6.9% other ethnicities. The mean body Figure 1 ). Angiotensin-converting enzyme 2 (ACE2) serves as a receptor for both SARS-CoV-1 and SARS-CoV-2. Researchers have raised the concerns that the use of Renin-angiotensin-aldosterone-system inhibitors could be associated with a higher risk of infection. In addition, COVID-19 infection is well-known to increase predisposition to hypercoagulability, resulting in thromboinflammation in patients. Some studies suggest that patients with COVID-19 taking antiplatelets had less severe infection, whereas others showed no beneficial effect of antiplatelets. We compared patients taking only antiplatelets (group 1) with those taking both RAS inhibitors and antiplatelets (group 2). Group 2 had a significantly higher mortality in 90 days. It could be possibly explained by the increased expression or activation of some receptors on platelets worsening the thromboinflammation systemically. However, patients who were on RAS inhibitors may have more comorbidities such as CKDs, hypertension, and DM with complications such as proteinuria. The logistic regression model indicated that only age, hospital length of stay, mechanical ventilation, oxygen requirement, hypertension, history of AFib, and acute myocardial infarction during hospitalization were independent predictors for 90-day mortality in all groups after adjusting for hypertension, diabetes, CKD, and DM. The model however showed that neither the use of antiplatelets nor combination of antiplatelets and RAS inhibitors was the independent predictor of mortality. Consistent with international society recommendations and clinical trials, we suggest continuing reninangiotensin system inhibitor therapy in patients admitted to hospital with COVID-19 12,13 because several cardiac-related comorbidities including hypertension and acute myocardial are independent factors for higher mortality themselves. Further clinical trials and, more importantly, translational research is needed to investigate the causal inference on antecedent usage of antiplatelets and/or RAS inhibitors in patients with COVID-19.

Severe Sars-CoV-2 Infection

To the Editor: Malignant hyperthermia (MH) is an uncommon but potentially life-threatening pharmacogenetic disorder that affects skeletal muscles. It is seen in response to volatile anesthetic agents and depolarizing neuromuscular blocker (NM blocker), succinylcholine. MH occurrence with a nondepolarizing NM blocker is a very rare phenomenon. Here, we report a case of cisatracurium-induced MH in an intensive care setting.

A 60-year-old gentleman with a medical history significant for dyslipidemia and solitary kidney was hospitalized because of worsening shortness of breath. He tested positive for SARS-CoV-2 6 days before presentation. His vitals on presentation: oxygen saturation of 92% on heated high flow nasal cannula with FiO2 60%, blood pressure 130/80 mm Hg, heart rate 95/min, and respiratory rate 48/min. Physical examination was unremarkable except for coarse breath sounds. Computed tomography angiogram of the chest was negative for pulmonary embolism; however, it showed extensive bilateral ground-glass airspace opacities. He was started on dexamethasone, remdesivir, and broadspectrum antibiotics. His respiratory distress worsened,

Is there an association between COVID-19 mortality and the reninangiotensin system? A call for epidemiologic investigations

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat

Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan

Kidney and lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19

Antecedent Administration of angiotensin-converting enzyme inhibitors or angiotensin II receptor Antagonists and survival after hospitalization for COVID-19 syndrome

Platelet gene expression and function in patients with COVID-19

Platelets can associate with SARS-cov-2 RNA and are hyperactivated in COV-ID-19

Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran

Mortality and prehospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease

Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19

Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial